大腸がん診断市場- 世界の産業規模、動向、機会、予測、診断タイプ別、用途別、地域別、競合別、2020～2030年

大腸がん診断の世界市場規模は2024年に180億5,000万米ドルとなり、予測期間中のCAGRは4.85%で2030年には237億9,000万米ドルに達すると予測されています。

世界の大腸がん診断市場は、大腸がんの有病率の上昇、早期発見に対する意識の高まり、診断技術の継続的な進歩に牽引され、大きな成長を遂げています。大腸がんは世界中で最も多く診断されるがんの一つであり、早期診断は患者の転帰と生存率の改善に重要な役割を果たしています。例えば、国際がん研究機関（IARC）によると、2022年には世界中で190万人以上の大腸がん患者が診断されます。最も一般的ながんのひとつである大腸がんは、経済的にも社会的にも大きな課題を突きつけています。このような有病率の増加は、効果的な診断ソリューションに対する需要の高まりを強調しており、この疾患の世界の負担の増大に対処するための早期発見とスクリーニング方法の改善が急務であることを強調しています。

ヘルスケアシステムが予防医療と早期発見をますます重視するようになるにつれ、先進的な診断ツールに対する需要が高まり続けています。主要診断方法には、大腸内視鏡検査、CTスキャン、MRIなどの画像診断技術、バイオマーカー検査、便検査、血液検査などがあります。これらの方法は人工知能や機械学習の統合によって進化しており、診断精度を高め、早期発見を可能にしています。非侵襲的な在宅スクリーニングソリューションも、利便性と患者のコンプライアンス向上を提供することから、人気を集めています。

ヘルスケアプロバイダ、特に病院や診断ラボが大腸がん診断の主要ユーザーであり、その理由は先進的機器と訓練を受けた専門家へのアクセスにあります。しかし、セルフスクリーニングキットやモバイル医療サービスの利用可能性の高まりにより、特に先進諸国では、需要の一部が在宅診断にシフトしつつあります。地域的には、北米のや欧州のような先進地域が、その強固なヘルスケアインフラと高い検診率によって現在市場を独占している一方で、アジア太平洋のやラテンアメリカ新興経済諸国は急速に拡大しています。この成長の原動力となっているのは、ヘルスケア投資の増加、啓発プログラムの増加、診断施設へのアクセスの改善です。大腸がん診断市場は、技術革新、診断企業間の戦略的パートナーシップ、定期的な検診を推進する政府のイニシアティブに支えられ、着実に拡大するものと考えられます。患者の意識が高まり続け、診断オプションがより利用しやすくなるにつれて、同市場は大腸がんとの世界の闘いにおいてますます重要な役割を果たすようになると予想されます。

主要市場促進要因

大腸がん罹患率の上昇

主要市場課題

高度診断の高コスト

主要市場動向

非侵襲的・在宅検査へのシフト

目次

第1章 概要

• 市場の定義
• 市場の範囲
  • 対象市場
  • 調査対象年
  • 主要市場セグメンテーション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の大腸がん診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 診断タイプ別（画像診断、便検査、生検、その他）
  • 用途別（病院と専門クリニック、外来診療センターなど）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2024年）
• 市場マップ

第6章 北米の大腸がん診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の大腸がん診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋の大腸がん診断市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア

第9章 南米の大腸がん診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの大腸がん診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • アラブ首長国連邦
  • サウジアラビア
  • 南アフリカ

第11章 市場力学

• 促進要因
  • 大腸がんの発生率の増加
  • 鎮静的なライフスタイル
  • 研究開発の成長
• 課題

第12章 市場動向と発展

第13章 臨床検査分析

第14章 競合情勢

• Abbott Laboratories
• Illumina, Inc.
• Sysmex Corporation
• Beckman Coulter
• Siemens Healthineers AG
• Quest Diagnostics
• Danaher Corporation
• Cancer Genetics Inc.
• Biocept Inc.
• Epigenomics AG

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Colorectal Cancer Diagnostics Market was valued at USD 18.05 billion in 2024 and is expected to reach USD 23.79 billion by 2030 with a CAGR of 4.85% during the forecast period. The global colorectal cancer diagnostics market is witnessing significant growth, driven by a rising prevalence of colorectal cancer, growing awareness about early detection, and continuous advancements in diagnostic technologies. Colorectal cancer ranks among the most commonly diagnosed cancers worldwide, and early diagnosis plays a critical role in improving patient outcomes and survival rates. For instance, according to the International Agency for Research on Cancer (IARC), over 1.9 million colorectal cancer cases were diagnosed worldwide in 2022. As one of the most common cancers, colorectal cancer poses significant economic and societal challenges. This increasing prevalence underscores a rising demand for effective diagnostic solutions, highlighting the urgent need for early detection and improved screening methods to manage the growing global burden of the disease.

As healthcare systems increasingly emphasize preventive care and early detection, the demand for advanced diagnostic tools continues to rise. Key diagnostic methods include imaging techniques such as colonoscopy, CT scans, and MRI, along with biomarker testing, stool-based tests, and blood-based assays. These methods are evolving with the integration of artificial intelligence and machine learning, enhancing diagnostic accuracy and enabling earlier detection. Non-invasive and at-home screening solutions are also gaining popularity, as they offer convenience and improved patient compliance.

Healthcare providers, especially hospitals and diagnostic laboratories, are the primary users of colorectal cancer diagnostics, owing to their access to advanced equipment and trained professionals. However, the growing availability of self-screening kits and mobile health services is shifting some of the demand toward home-based diagnostics, particularly in developed countries. Geographically, while developed regions like North America and Europe currently dominate the market due to their robust healthcare infrastructure and high screening rates, emerging economies in Asia-Pacific and Latin America are rapidly expanding. This growth is fueled by rising healthcare investments, increasing awareness programs, and improving access to diagnostic facilities. The colorectal cancer diagnostics market is set to expand steadily, supported by technological innovations, strategic partnerships among diagnostic firms, and governmental initiatives promoting regular screening. As patient awareness continues to grow and diagnostic options become more accessible, the market is expected to play an increasingly vital role in the global fight against colorectal cancer.

Key Market Drivers

Rising Incidence of Colorectal Cancer

The rising incidence of colorectal cancer is a critical driver of growth in the global colorectal cancer diagnostics market. For instance, in 2023, research from the National Center for Biotechnology Information reported that the incidence of colorectal cancer in Japan was approximately 26.7 per 100,000 men and 22.7 per 100,000 women aged 40 to 44. This highlights the growing prevalence of colorectal cancer in this age group within the country. Colorectal cancer is now one of the most common cancers worldwide, affecting both men and women across diverse age groups. This upward trend is closely linked to changes in lifestyle, including increased consumption of processed foods, sedentary behavior, obesity, alcohol intake, and smoking. The aging global population significantly contributes to the higher prevalence of the disease, as the risk of colorectal cancer increases with age. As the number of cases continues to climb, there is a corresponding surge in demand for early and accurate diagnostic tools. The UK is witnessing an increase in colorectal cancer cases, driven by an aging population, sedentary lifestyles, and changing dietary habits. This highlights the urgent need for comprehensive diagnostic solutions. For instance, Cancer Research UK reports that around 44,100 new bowel cancer cases are diagnosed annually, emphasizing the importance of early detection and effective screening programs. Early detection of colorectal cancer significantly improves prognosis and treatment outcomes. Consequently, healthcare systems across the world are investing more in screening and diagnostic technologies. Colonoscopy remains the gold standard, but there is growing interest in non-invasive tests such as stool-based DNA assays, fecal immunochemical tests (FIT), and blood-based biomarker tests. The increase in cases has also prompted public health authorities to launch nationwide screening programs and awareness campaigns, particularly in developed countries. In emerging economies, rising disease burden and healthcare infrastructure improvements are leading to greater adoption of diagnostic services. This rise in incidence is not just increasing volume demand but also encouraging innovation in diagnostic approaches. Companies are developing faster, more sensitive, and patient-friendly diagnostic solutions, including AI-powered imaging and home-based test kits. Overall, the growing number of colorectal cancer cases globally is fueling advancements and expansions within the diagnostics market, making it a key area of focus for both public and private healthcare stakeholders.

Key Market Challenges

High Cost of Advanced Diagnostics

The high cost of advanced diagnostics remains a significant barrier to the widespread adoption of colorectal cancer screening and detection methods across the globe. While technological innovations such as high-definition colonoscopy, molecular biomarker testing, next-generation sequencing (NGS), and liquid biopsies have significantly improved diagnostic accuracy and patient outcomes, they often come with a high price tag. These costs can be prohibitive for both healthcare providers and patients, particularly in low- and middle-income countries where healthcare resources are limited and out-of-pocket payments are common. Advanced diagnostics typically require sophisticated equipment, skilled personnel, and specialized laboratory infrastructure, all of which contribute to high operational costs. For example, procedures like colonoscopy not only involve expensive imaging devices but also require sedation, trained endoscopists, and post-procedure recovery, adding to the overall expense. Similarly, liquid biopsies and genomic tests demand advanced platforms and reagents, which can drive up costs further. The financial burden can deter individuals from undergoing routine screening, especially in regions without robust public health coverage or insurance systems. As a result, many cases are detected at later stages when treatment is more complex and expensive, ultimately increasing the overall burden on healthcare systems.

To address this challenge, governments and healthcare stakeholders are exploring cost-effective alternatives, such as fecal immunochemical tests (FIT) and stool DNA tests, which offer reasonable sensitivity at a lower cost. The efforts are being made to subsidize testing and expand public screening programs. Despite these efforts, the affordability gap remains a key issue. For the global colorectal cancer diagnostics market to achieve inclusive growth and equitable outcomes, reducing the cost of advanced diagnostics and improving access across socioeconomic groups must become a central focus of future strategies and innovations.

Key Market Trends

Shift Towards Non-Invasive and Home-Based Testin

The global colorectal cancer diagnostics market is witnessing a significant shift towards non-invasive and home-based testing methods, reflecting a broader trend aimed at improving patient comfort, compliance, and early detection rates. Traditional diagnostic procedures like colonoscopy, while effective, are invasive, often uncomfortable, and require specialized medical facilities and trained personnel. These factors have historically limited widespread screening, particularly among populations reluctant to undergo invasive procedures or those with limited access to healthcare centers. Non-invasive tests such as fecal immunochemical tests (FIT), stool DNA assays, and emerging blood-based biomarker tests offer a convenient and less intrusive alternative. These tests can detect early signs of colorectal cancer or precancerous lesions through analysis of stool or blood samples, allowing for easier screening in routine check-ups or even at home. The availability of home-based testing kits has particularly boosted participation in colorectal cancer screening programs by providing privacy, reducing the need for hospital visits, and simplifying sample collection.

This shift is also supported by advancements in molecular biology and biomarker discovery, which have enhanced the sensitivity and specificity of non-invasive tests. Improved diagnostic accuracy helps reduce false positives and negatives, thereby optimizing patient management and follow-up procedures. In developing countries and remote areas, where access to specialized medical facilities is limited, non-invasive and home-based testing has become an essential tool in expanding screening coverage. It also aligns with growing patient preference for minimally disruptive healthcare experiences. The move toward non-invasive and home-based colorectal cancer diagnostics is driving market growth by making early detection more accessible, affordable, and acceptable, ultimately improving outcomes and reducing the global colorectal cancer burden.

Key Market Players

• Abbott Laboratories
• Illumina, Inc.
• Sysmex Corporation
• Beckman Coulter
• Siemens Healthineers AG
• Quest Diagnostics
• Danaher Corporation
• Cancer Genetics Inc.
• Biocept Inc.
• Epigenomics AG

Report Scope:

In this report, the Global Colorectal Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Colorectal Cancer Diagnostics Market, By Diagnosis Type:

• Diagnostics Imaging
• Stool Test
• Biopsy
• Others

Colorectal Cancer Diagnostics Market, By Application:

• Hospitals & Specialty Clinics
• Ambulatory Care Centers
• Others

Colorectal Cancer Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Colorectal Cancer Diagnostics Market.

Available Customizations:

Global Colorectal Cancer Diagnostics Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Colorectal Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis Type (Diagnostics Imaging, Stool Test, Biopsy, Others)
    • 5.2.1.1. By Diagnostics Imaging (Sigmoidoscopy, Colonoscopy, and Others)
    • 5.2.1.2. By Stool Test (Guaiac FOBT, Fecal immunochemical (or immunohistochemical) Test (FIT), FIT-DNA Test)
    • 5.2.1.3. By Biopsy (Image Guided Biopsy, Liquid Biopsy, Others)
  • 5.2.2. By Application (Hospitals & Specialty Clinics, Ambulatory Care Centers, and Others)
  • 5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle-East and Africa)
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Colorectal Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Colorectal Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Colorectal Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Colorectal Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis Type
      • 6.3.3.2.2. By Application

7. Europe Colorectal Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Colorectal Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Colorectal Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Colorectal Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Colorectal Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnosis Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Colorectal Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnosis Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Colorectal Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Colorectal Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis Type
      • 8.3.1.2.2. By Application
  • 8.3.2. Japan Colorectal Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis Type
      • 8.3.2.2.2. By Application
  • 8.3.3. India Colorectal Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Colorectal Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnosis Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Colorectal Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnosis Type
      • 8.3.5.2.2. By Application

9. South America Colorectal Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Colorectal Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Colorectal Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Colorectal Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Colorectal Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnosis Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Colorectal Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnosis Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Colorectal Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnosis Type
      • 10.3.2.2.2. By Application
  • 10.3.3. South Africa Colorectal Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnosis Type
        • 10.3.3.2.1.1. By Application

11. Market Dynamics

• 11.1. Drivers
  • 11.1.1. Increasing Incidence of Colorectal Cancer
  • 11.1.2. Sedative Lifestyle
  • 11.1.3. Growth in Research & Development
• 11.2. Challenges

12. Market Trends & Developments

13. Clinical Trial Analysis

• 13.1. Ongoing Clinical Trials
• 13.2. Completed Clinical Trials
• 13.3. Terminated Clinical Trials
• 13.4. Breakdown of Pipeline, By Development Phase
• 13.5. Breakdown of Pipeline, By Status
• 13.6. Breakdown of Pipeline, By Study Application
• 13.7. Breakdown of Pipeline, By Region
• 13.8. Clinical Trials Heat Map

14. Competitive Landscape

• 14.1. Abbott Laboratories
• 14.2. Illumina, Inc.
• 14.3. Sysmex Corporation
• 14.4. Beckman Coulter
• 14.5. Siemens Healthineers AG
• 14.6. Quest Diagnostics
• 14.7. Danaher Corporation
• 14.8. Cancer Genetics Inc.
• 14.9. Biocept Inc.
• 14.10. Epigenomics AG

15. Strategic Recommendations

16. About Us and Disclaimer